DK2350096T3 - Fremgangsmåder til behandling af hepatisk encephalopati - Google Patents
Fremgangsmåder til behandling af hepatisk encephalopati Download PDFInfo
- Publication number
- DK2350096T3 DK2350096T3 DK09818544.0T DK09818544T DK2350096T3 DK 2350096 T3 DK2350096 T3 DK 2350096T3 DK 09818544 T DK09818544 T DK 09818544T DK 2350096 T3 DK2350096 T3 DK 2350096T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- hepatic encephalopathy
- treating hepatic
- treating
- encephalopathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emergency Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10234908P | 2008-10-02 | 2008-10-02 | |
PCT/US2009/059321 WO2010040020A1 (en) | 2008-10-02 | 2009-10-02 | Methods of treating hepatic encephalopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2350096T3 true DK2350096T3 (da) | 2020-03-02 |
Family
ID=42073897
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09818544.0T DK2350096T3 (da) | 2008-10-02 | 2009-10-02 | Fremgangsmåder til behandling af hepatisk encephalopati |
DK19207534.9T DK3628319T3 (da) | 2008-10-02 | 2009-10-02 | Behandling af hepatisk encefalopati ved anvendelse af rifaximin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19207534.9T DK3628319T3 (da) | 2008-10-02 | 2009-10-02 | Behandling af hepatisk encefalopati ved anvendelse af rifaximin |
Country Status (20)
Country | Link |
---|---|
US (11) | US20100204173A1 (da) |
EP (2) | EP2350096B1 (da) |
JP (2) | JP6037615B2 (da) |
CN (1) | CN102245615A (da) |
AU (1) | AU2009298389C1 (da) |
BR (1) | BRPI0920465A2 (da) |
CA (1) | CA2739436C (da) |
CY (1) | CY1122806T1 (da) |
DK (2) | DK2350096T3 (da) |
ES (1) | ES2770308T3 (da) |
FI (1) | FI3628319T3 (da) |
HR (1) | HRP20200284T1 (da) |
HU (1) | HUE048293T2 (da) |
IL (1) | IL212055A0 (da) |
LT (2) | LT3628319T (da) |
MX (2) | MX364102B (da) |
PL (2) | PL3628319T3 (da) |
PT (2) | PT3628319T (da) |
SI (2) | SI3628319T1 (da) |
WO (1) | WO2010040020A1 (da) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
DK1698630T3 (da) | 2005-03-03 | 2014-12-08 | Alfa Wassermann Spa | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
WO2010040020A1 (en) * | 2008-10-02 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
EP3964066A1 (en) * | 2009-06-02 | 2022-03-09 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
AU2010260089B2 (en) * | 2009-06-15 | 2015-05-14 | Salix Pharmaceuticals, Inc. | Modulation of systemic exposure to rifaximin |
US8772242B2 (en) | 2009-10-26 | 2014-07-08 | Thomas Julius Borody | Therapy for enteric infections |
CN103124559B (zh) | 2010-08-04 | 2017-03-29 | 托马斯·朱利叶斯·波洛迪 | 用于粪便菌群植入的组合物及其制备和使用方法以及递送该组合物的装置 |
WO2012076832A1 (en) * | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
CA3119918A1 (en) | 2011-03-09 | 2012-09-13 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
WO2013067394A1 (en) | 2011-11-02 | 2013-05-10 | Salix Pharmaceuticals, Ltd | Methods for treating irritable bowel syndrome (ibs) and infections |
WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
ITBO20120368A1 (it) * | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
CA2883851A1 (en) * | 2012-09-13 | 2014-03-20 | Salix Pharmaceuticals, Inc. | Methods of improving long-term survival and reducing hospitalization readmission rates for subjects suffering from hepatic encephalopathy |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US20150335615A1 (en) * | 2013-01-04 | 2015-11-26 | Toshihisa Kawai | Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
WO2014176632A1 (en) * | 2013-04-30 | 2014-11-06 | Borody Thomas J | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
CN103340856A (zh) * | 2013-07-09 | 2013-10-09 | 荣港生技医药科技(北京)有限公司 | 一种利福昔明药物组合物及其制备方法 |
JP6543633B2 (ja) | 2014-01-29 | 2019-07-10 | ウメクライン コグニション アーベー | 肝性脳症の治療において使用するためのステロイド化合物 |
ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
ES2810010T3 (es) | 2014-05-12 | 2021-03-08 | Alfasigma Spa | Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME |
WO2016003536A1 (en) * | 2014-06-30 | 2016-01-07 | Salix Pharmaceuticals, Inc. | Methods for retreating irritable bowel syndrome (ibs) |
TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ab公司 | 新穎化合物 |
EP3294307A4 (en) | 2015-05-14 | 2019-01-23 | Crestovo Holdings Llc | COMPOSITIONS FOR TRANSPLANTATION OF FECAL FLORA AND METHODS OF PREPARATION AND USE THEREOF, AND DEVICES FOR THEIR ADMINISTRATION |
CA2986485A1 (en) | 2015-05-22 | 2016-12-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
CA3010865A1 (en) * | 2016-01-08 | 2017-07-13 | Colonaryconcepts Llc | Food based delivery of therapeutic agent for treatment of hepatic encephalopathy |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
EP4137132A1 (en) | 2016-09-30 | 2023-02-22 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
CN106822125A (zh) * | 2017-02-28 | 2017-06-13 | 丹诺医药(苏州)有限公司 | 一种利福霉素‑喹嗪酮双靶标分子的新用途 |
CN106822119A (zh) * | 2017-02-28 | 2017-06-13 | 丹诺医药(苏州)有限公司 | 一种利福霉素‑硝基咪唑偶联分子的新用途 |
US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
WO2018218159A1 (en) | 2017-05-26 | 2018-11-29 | Crestovo Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
EP3664823B1 (en) | 2017-08-07 | 2024-06-05 | Finch Therapeutics Holdings LLC | Composition for use in preventing or treating an enterococcal blood stream infection |
JP2021502382A (ja) | 2017-11-10 | 2021-01-28 | コスモ・テクノロジーズ・リミテツド | 経口リファマイシンsv組成物 |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
CA3114423A1 (en) | 2018-09-27 | 2020-04-02 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
AU2020276213A1 (en) | 2019-05-10 | 2021-10-28 | Société des Produits Nestlé S.A. | Methods for improving the quality of life of a patient with a peanut allergy |
US20230111568A1 (en) * | 2020-03-24 | 2023-04-13 | Bausch Health Ireland Limited | Solid dispersions of rifaximin for the treatment of overt hepatic encephalopathy |
WO2023225073A1 (en) * | 2022-05-18 | 2023-11-23 | Virginia Commonwealth University | Methods for treatment of cognitive impairment in cirrhosis patients |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3132910A (en) | 1962-03-26 | 1964-05-12 | Eastman Kodak Co | Cabinetry structure |
IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
US4343785A (en) | 1981-08-10 | 1982-08-10 | Basf Wyandotte Corporation | Gel dentifrice compositions |
IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
AU5171293A (en) | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US6562629B1 (en) * | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
ES2114502B1 (es) | 1996-07-29 | 1999-07-01 | Univ Santiago Compostela | Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas. |
WO1998010649A1 (en) | 1996-09-13 | 1998-03-19 | University Technology Corporation | Biocompatible cationic detergents and uses therefor |
IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
US20020028764A1 (en) | 2000-09-04 | 2002-03-07 | Aarhus Amt. | Treatment of acute and chronic liver disease |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
US20040229948A1 (en) * | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
US20040077533A1 (en) * | 2002-05-23 | 2004-04-22 | Sayada Chalom B. | Methods and compositions for treating bacterial infections and diseases associated therewith |
US20090149453A1 (en) * | 2002-05-23 | 2009-06-11 | Activbiotics Pharma Llc | Methods and compositions for treating bacterial infections and diseases associated therewith |
ATE448775T1 (de) * | 2002-08-29 | 2009-12-15 | Activbiotics Pharma Llc | Rifalazil zur behandlung von infektionen mit clostridium difficile |
TW200418485A (en) * | 2002-09-23 | 2004-10-01 | Activbiotics Inc | Rifalazil compositions and therapeutic regimens |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US7256202B2 (en) | 2003-12-31 | 2007-08-14 | Halow George M | Composition and method for treatment of hepatic encephalopathy |
EP2319581B1 (en) | 2004-11-26 | 2015-02-25 | UCL Business PLC | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
US8003118B2 (en) * | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
DK1698630T3 (da) * | 2005-03-03 | 2014-12-08 | Alfa Wassermann Spa | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater |
US20090233888A1 (en) | 2005-03-23 | 2009-09-17 | Usc Stevens, University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
WO2007103448A2 (en) | 2006-03-09 | 2007-09-13 | Salix Pharmaceuticals, Inc. | Rifaximin anti-rectal dysfunction preparation |
AU2007275034A1 (en) | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
CN104382900A (zh) | 2006-08-02 | 2015-03-04 | 萨利克斯药品公司 | 治疗放射性肠炎的组合物和方法 |
CN101534840A (zh) | 2006-08-02 | 2009-09-16 | 萨利克斯药品公司 | 治疗放射性肠炎的方法 |
US8633234B2 (en) | 2006-09-22 | 2014-01-21 | Cipla Limited | Rifaximin |
US20100136125A1 (en) | 2006-12-28 | 2010-06-03 | Jacobus Pharmaceutical Company, Inc. | Method of treating inflammatory bowel disease |
SI2011486T1 (sl) | 2007-07-06 | 2012-10-30 | Lupin Ltd | Farmacevtski sestavki rifaksimina |
WO2009008005A1 (en) * | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
UA101829C2 (uk) * | 2008-02-25 | 2013-05-13 | Саликс Фармасьютикалз, Лтд. | ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ |
US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
PL2252148T3 (pl) | 2008-02-26 | 2019-09-30 | Salix Pharmaceuticals, Ltd. | Sposoby leczenia zespołu jelita drażliwego |
WO2010040020A1 (en) * | 2008-10-02 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US7928115B2 (en) * | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
US20100317681A1 (en) | 2009-06-15 | 2010-12-16 | Salix Pharmaceuticals, Ltd. | Modulation of systemic exposure to rifaximin |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
EP3964066A1 (en) | 2009-06-02 | 2022-03-09 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
DE102009052972A1 (de) | 2009-11-12 | 2011-09-15 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm |
EP2340812A1 (en) | 2009-12-18 | 2011-07-06 | Ferring International Center S.A. | Granules for pharmaceutical preparations, methods and apparatus for their production |
LT2608792T (lt) | 2010-08-26 | 2018-01-10 | Boehringer Ingelheim International Gmbh | Egfr inhibitoriaus vartojimo būdai |
KR20130027255A (ko) * | 2011-09-07 | 2013-03-15 | 삼성전자주식회사 | 키 조립체 및 이를 구비한 회전식 입력 장치 |
PT2785349T (pt) | 2011-11-30 | 2019-12-11 | Astrazeneca Ab | Tratamento combinado de cancro |
CN106462181B (zh) | 2014-04-29 | 2019-10-25 | 惠普发展公司,有限责任合伙企业 | 用于计算装置的铰接组件 |
US20160191956A1 (en) * | 2014-12-15 | 2016-06-30 | Cable Television Laboratories, Inc. | Software defined networking in a cable tv system |
SI3302565T1 (sl) | 2015-06-04 | 2020-02-28 | Pfizer Inc. | Trdne farmacevtske oblike palbocikliba |
-
2009
- 2009-10-02 WO PCT/US2009/059321 patent/WO2010040020A1/en active Application Filing
- 2009-10-02 CN CN2009801490791A patent/CN102245615A/zh active Pending
- 2009-10-02 MX MX2014013652A patent/MX364102B/es unknown
- 2009-10-02 ES ES09818544T patent/ES2770308T3/es active Active
- 2009-10-02 LT LTEP19207534.9T patent/LT3628319T/lt unknown
- 2009-10-02 PT PT192075349T patent/PT3628319T/pt unknown
- 2009-10-02 LT LTEP09818544.0T patent/LT2350096T/lt unknown
- 2009-10-02 MX MX2011003548A patent/MX2011003548A/es active IP Right Grant
- 2009-10-02 AU AU2009298389A patent/AU2009298389C1/en active Active
- 2009-10-02 PL PL19207534.9T patent/PL3628319T3/pl unknown
- 2009-10-02 HU HUE09818544A patent/HUE048293T2/hu unknown
- 2009-10-02 US US12/572,344 patent/US20100204173A1/en not_active Abandoned
- 2009-10-02 PT PT98185440T patent/PT2350096T/pt unknown
- 2009-10-02 EP EP09818544.0A patent/EP2350096B1/en active Active
- 2009-10-02 CA CA2739436A patent/CA2739436C/en active Active
- 2009-10-02 JP JP2011530261A patent/JP6037615B2/ja active Active
- 2009-10-02 DK DK09818544.0T patent/DK2350096T3/da active
- 2009-10-02 SI SI200932192T patent/SI3628319T1/sl unknown
- 2009-10-02 BR BRPI0920465-2A patent/BRPI0920465A2/pt not_active Application Discontinuation
- 2009-10-02 FI FIEP19207534.9T patent/FI3628319T3/fi active
- 2009-10-02 DK DK19207534.9T patent/DK3628319T3/da active
- 2009-10-02 SI SI200932045T patent/SI2350096T1/sl unknown
- 2009-10-02 EP EP19207534.9A patent/EP3628319B1/en active Active
- 2009-10-02 PL PL09818544T patent/PL2350096T3/pl unknown
-
2011
- 2011-03-31 US US13/077,373 patent/US20110243879A1/en not_active Abandoned
- 2011-03-31 IL IL212055A patent/IL212055A0/en active IP Right Grant
-
2013
- 2013-02-15 US US13/768,617 patent/US8969398B2/en active Active
-
2015
- 2015-02-03 US US14/612,697 patent/US9629829B2/en active Active
- 2015-05-21 JP JP2015103724A patent/JP2015166381A/ja active Pending
-
2017
- 2017-03-16 US US15/460,704 patent/US9949958B2/en active Active
-
2018
- 2018-03-15 US US15/922,010 patent/US10335397B2/en active Active
-
2019
- 2019-05-16 US US16/414,018 patent/US10709694B2/en active Active
-
2020
- 2020-02-19 HR HRP20200284TT patent/HRP20200284T1/hr unknown
- 2020-02-21 CY CY20201100167T patent/CY1122806T1/el unknown
- 2020-06-05 US US16/893,651 patent/US20200368213A1/en not_active Abandoned
-
2021
- 2021-03-26 US US17/213,678 patent/US11633384B2/en active Active
-
2023
- 2023-03-06 US US18/117,899 patent/US20240066010A1/en active Pending
- 2023-04-18 US US18/135,823 patent/US20230330071A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2350096T3 (da) | Fremgangsmåder til behandling af hepatisk encephalopati | |
DK2271642T3 (da) | Pyridylinhibitorer af hedgehog signalering | |
DK2293816T3 (da) | Fremgangsmåder til behandling af reumatoid arthritis | |
DK2325648T3 (da) | Fremgangsmåde til detektering af cancer | |
DK2204453T3 (da) | Fremgangsmåde til celle-fri fremstilling af kemikalier | |
DK2212070T3 (da) | Fremgangsmåde til behandling af træ | |
DK2498771T3 (da) | Anvendelse af bethanechol til behandling af xerostomi | |
DK2346321T4 (da) | Sammensætning til forbedring af effektiviteten af herbicider | |
DK2358714T3 (da) | Alkylcyclohexylethere af dihydrotetraazabenzoazulener | |
DK3412687T3 (da) | Fremgangsmåder til behandling af dlbcl | |
DK2350116T3 (da) | Behandling af biofilm | |
DK2111555T3 (da) | Diagnosticering af præeklampsi | |
DK2361388T3 (da) | Fremgangsmåder til karakterisering af molekyler | |
DK2382232T3 (da) | Fremgangsmåde til fremstilling af bivalirudin | |
DK3214083T3 (da) | Fremgangsmåde til fremstilling af quinolonforbindelser | |
DK2326332T3 (da) | Fremgangsmåde til behandling af sygdomme | |
EP2437603A4 (en) | METHODS OF TREATING HEPATIC ENCEPHALOPATHY | |
DK2265415T3 (da) | Fremgangsmåde til permanent samling af emner | |
DK2501381T3 (da) | Behandling af atrieflimmer | |
DK2271634T3 (da) | Modulatorer af dopamin-neurotransmission | |
DK2285416T3 (da) | Konjugat til behandlingen af mesotheliom | |
DK2190451T3 (da) | Behandling af atherosklerose | |
DK3081097T3 (da) | Sammensætning til behandling af infertilitet | |
BRPI0920449A2 (pt) | divulgação de serviços online | |
DK2151429T3 (da) | Fremgangsmåde til fremstilling af agomelatin |